1. Perlis RH, et al. Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study. 2. Depression & Anxiety. 2018;35(10):946-952. doi:10.1002/da.22742 https://www.cdc.gov/workplacehealthpromotion/model/evaluation/productivity.html 3.https://www.nature.com/articles/tp20132
Incite Health will provide communication options to you that can help build awareness of the PGx Testing Wellness Program through emails to employees as well as having educational videos available on the Employee Portal to learn more about the benefits of PGx testing.
For a new drug to be included within an Incite Health PGx report, clinical evidence for the specific Drug-Gene interaction must be clinically confirmed and reported by one of three regulatory organizations – the FDA, CPIC (Clinical Pharmacogenetics Implementation Consortium) or PharmGKB (Pharmacogenomics Knowledge Base). These organizations review clinical studies and publish the guidelines for PGx reporting based on this data.
As new medications are evaluated, any Drug-Gene interactions are reported via these organizations; if the associated genes are included within Incite Health’s PGx report then no repeat testing is required – we will simply re-run the reports to capture these new medication guidelines. Only in instances where a new gene that is not covered under our current PGx test is reported, would another separate PGx test be recommended.
Incite Health’s PGx report only includes drugs with clinically confirmed Drug-Gene interactions and the associated guidelines published by the FDA, CPIC or PharmGKB for the genes profiled within Incite Health’s PGx test. If a medication is not listed in our report, it is because there are no confirmed Drug-Gene interactions, or that the gene responsible is not included in our test.
Specialty drugs such as Ozempic™ and Zepbound™ are new to the market, and there are still ongoing PGx clinical studies evaluating any Drug-Gene interactions. As soon as the FDA, CPIC or PharmGKB issue any PGx guidelines on the use of these drugs, then Incite Health will, wherever appropriate, update our PGx reporting.
With the Incite Health PGx Testing Program, your employees will have access to our Pharmacist of Record who will be available to help interpret your employees’ PGx results and provide insights to help in their medication management regimen. Additionally, the PGx results will also be sent to the employee’s healthcare provider so that their physician can take action with the employee as well to ensure compliance. All these actions should lead to fewer employee sick days, less absenteeism, and fewer trips to the ER – improving the wellness of your employees and reducing overall costs.
PGx testing is covered by Medicare, Medicaid, and most insurance companies under specific conditions. We recommend that you reach out to your healthcare insurance provider for more details.